N-[1-[2-(1H-indol-4-yloxy)ethyl]piperidin-4-yl]naphthalene-1-sulfonamide | 1417308-31-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-[1-[2-(1H-indol-4-yloxy)ethyl]piperidin-4-yl]naphthalene-1-sulfonamide
• CAS: 1417308-31-6
• 化学式: C₂₅H₂₇N₃O₃S
• 分子量: 449.574
• InChiKey: RAMVBBFPBVFMCU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  32
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  82.8
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• SULPHONAMIDE DERIVATIVES OF ALICYCLIC AMINES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES
  申请人：Kolaczkowski Marcin

  公开号：US20140135310A1

  公开（公告）日：2014-05-15

  Sulphonamide derivatives of alicyclic amines of formula (I), wherein A represents naphthyl or 9- or 10-membered bicyclic group, consisting of benzene ring fused with 5- or 6-membered heterocyclic ring; D represents phenyl, naphthyl, 5-membered aromatic heterocyclic group, bicyclic group consisting of a ring selected from benzene and pyridine, fused with aromatic or non-aromatic 5-membered heterocyclic ring; p, r independently represent 0 or 1; x, z independently represent 1 or 2; n is 2 or 3; and enancjomers, pharmaceutically acceptable salts and solvates thereof. The compounds may be useful for the treatment and/or prevention of the central nervous system disorders.

  环脂肪胺的磺胺衍生物的化学式(I)，其中A代表萘基或9-或10-成员双环基团，由苯环与5-或6-成员杂环环融合而成；D代表苯基，萘基，5-成员芳香杂环基团，由苯环和吡啶中选择的环融合而成，与芳香或非芳香5-成员杂环环融合；p，r独立地代表0或1；x，z独立地代表1或2；n为2或3；其对映体，药学上可接受的盐及溶剂化合物。这些化合物可能对中枢神经系统疾病的治疗和/或预防有用。
• [EN] SULPHONAMIDE DERIVATIVES OF ALICYCLIC AMINES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES<br/>[FR] DÉRIVÉS SULPHONAMIDE D'AMINES ALICYCLIQUES UTILISÉS DANS LE TRAITEMENT DE MALADIES DU SYSTÈME NERVEUX CENTRAL
  申请人：ADAMED SP ZOO

  公开号：WO2013001505A2

  公开（公告）日：2013-01-03

  Sulphonamide derivatives of alicyclic amines of formula (I), wherein A represents naphthyl or 9- or 10-membered bicyclic group, consisting of benzene ring fused with -or 6-membered heterocyclic ring; D represents phenyl, naphthyl, 5-membered aromatic heterocyclic group, bicyclic group consisting of a ring selected from benzene and pyridine, fused with aromatic or non-aromatic 5-membered heterocyclic ring; r represents 0 or 1; x, z independently represent 1 or 2; n represents 3 and p represents 0, or n represents 2 and p represents 1;and enantiomers, pharmaceutically acceptable salts and solvates thereof. The compounds may be useful for the treatment and/or prevention of the central nervous system disorders (Formula I).